Bli medlem
Bli medlem

Du är här

2016-10-26

DBV Technologies: DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in the Journal of Allergy

--------------------------------------
| Press Release |
| |
|Montrouge, France, October 26, 2016 |
--------------------------------------

DBV Technologies Announces Publication of Positive Viaskin Peanut Data From NIAID-Sponsored Phase II Academic Study in theJournal of Allergy and Clinical Immunology
The study, CoFAR6, evaluated peanut-allergic patients 4 to 25 years of age

Primary endpoint of the study was met; greatest benefit observed in children

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT) today announced the publication of 12-month results from CoFAR6, a
Consortium of Food Allergy Research (CoFAR) study sponsored by the National
Institute of Allergy and Infectious Diseases (NIAID), part of the National
Institutes of Health (NIH), investigating the use of Viaskin Peanut for the
treatment of peanut-allergic patients 4 to 25 years of age. The primary
endpoint of the study, which measured a statistically significant
desensitization to peanut, was met, with a greater clinical benefit reported
in younger participants. The authors of the publication concluded that
Viaskin Peanut was safe and could potentially be a convenient mode of
treatment for peanut allergy.

Results from the CoFAR6 study were previously announced and presented at the
2016 American Academy of Allergy, Asthma&Immunology (AAAAI) Annual Meeting in
March 2016 in Los Angeles, CA.

"No FDA-approved treatment for peanut allergy exists today. Risks of severe
reactions from accidental exposure are a constant threat for these patients,
even when following a peanut-free diet,
" saidDr. Stacie Jones
, Professor of Pediatrics, University of Arkansas for Medical Sciences,
Arkansas Children's Hospital, Little Rock, AR, and lead author of the
publication. "A novel treatment that can provide an essential balance between
safety and
efficacy will be of key importance in the treatment of these patients. The
results from CoFAR6 with Viaskin Peanut are promising, and we are looking
forward to learning more about this new treatment modality.
"

Viaskin Peanut is the company's lead product candidate, which is based on
epicutaneous immunotherapy (EPIT), a proprietary technology platform that can
deliver biologically active compounds to the immune system through the skin.

The CoFAR6 study publication, titledEpicutaneous Immunotherapy for the
Treatment of Peanut Allergy in Children and
Young Adults,
was published online ahead of print in theJournal of Allergy and Clinical
Immunology
(JACI):www.jacionline.org/inpress(DOI: 10.1016/j.jaci.2016.08.017).

About the CoFAR6 Study

In October 2013, CoFAR launched a multi-center, randomized, double-blind,
placebo-controlled trial to evaluate Viaskin Peanut in children, adolescents
and young adults allergic to peanuts. This trial is sponsored and funded by
the NIAID and led by Dr. Stacie Jones. The CoFAR6 trial is being conducted in
five hospitals in the United States, and 75 patients were enrolled; 54
children four to 11 years of age and 21 adolescents and adults 12 to 25 years
of age. In CoFAR6, subjects were randomized 1:1:1 to two doses of Viaskin
Peanut (100 µg and 250 µg) or placebo. The primary outcome measure was
percent of patients desensitized to peanut protein during peanut protein oral
food challenge (OFC) at week 52. Responders were characterized as patients
who successfully passed a 5044 mg OFC or who successfully consumed a dose ten
times greater as compared to baseline.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform
with broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With this new
class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for
whom there are no approved treatments. DBV's food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV is also pursuing a human proof-of-concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis,
and exploring potential applications of its platform in vaccines and other
immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York,
NY. Company shares are traded on segment B of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our
website:www.dbv-technologies.com

Forward Looking Statements

This press release contains forward-looking statements, including statements
regarding the potential safety and efficacy of Viaskin Peanut and statements
reflecting management's expectations for clinical development of our product
candidates and the commercial potential of our product candidates. These
forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. Among the factors that could cause
actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the risk that
historical preclinical results may not be predictive of future clinical trial
results, and the risk that historical clinical trial results may not be
predictive of future trial results. A further list and description of these
risks, uncertainties and other risks can be found in the Company's regulatory
filings with the French Autorité des Marchés Financiers, the Company's
Securities and Exchange Commission filings and reports, including in the
Company's Annual Report on Form 20-F for the year ended December 31, 2015 and
future filings and reports by the Company. Existing and prospective investors
are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. DBV Technologies
undertakes no obligation to update or revise the information contained in
this Press Release, whether as a result of new information, future events or
circumstances or otherwise.

DBV Technologies Contact

Susanna Mesa

Senior Vice President, Strategy
+1 212-271-0861
susanna.mesa@dbv-technologies.com

Media Contact

Erinn White, Centron PR

+1-646-722-8822
ewhite@centronpr.com

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59
caroline@alizerp.com

PDF Version
http://hugin.info/156437/R/2051667/767665.pdf

---------------------------------------

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.